A new drug combo for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pucotenlimab, for people with advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread. The goal is to see if this treatment is safe and works well, especially for those with a protein called TROP2 on their cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced bile duct cancer, gallbladder cancer, or intrahepatic/extrahepatic cholangiocarcinoma that cannot be removed or has spread.
- You have not had certain prior treatments like TROP2-targeted therapy or immune checkpoint inhibitors.
- You have not had other cancers in the last 3 years, except for minor skin cancers or cervical cancer in situ.
- You are in good enough health to carry out daily activities (ECOG score 0 or 1) and have adequate organ function.
- You do not have active autoimmune diseases, active hepatitis B or C, or HIV/AIDS.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for advanced bile duct cancer (cholangiocarcinoma) that has not responded to previous treatment. The drugs work with your immune system to attack cancer cells, and may help slow the disease.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This study tests a new combination of two drugs for advanced bile duct or gallbladder cancer that has not responded to first-line immunotherapy and chemotherapy. The drugs target the TROP2 protein on cancer cells and boost the immune system to fight the cancer.
This trial tests a new drug called sacituzumab tirumotecan for people with advanced bile duct cancer that has grown after previous treatment. The drug targets a protein called TROP2 on cancer cells and may help shrink tumors or slow the disease.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.